Tim, an actual BEQVEZTM (fidanacogene elaparvovec- dzkt) patient, riding a bicycle with the words, "Tim, who received the BEQVEZ infusion in 2021" and "Tim participated in the BEQVEZ clinical study."

Tim, an actual BEQVEZTM (fidanacogene elaparvovec- dzkt) patient, riding a bicycle with the words, "Tim, who received the BEQVEZ infusion in 2021" and "Tim participated in the BEQVEZ clinical study."

Why gene therapy?

Tim, who received the BEQVEZ infusion in 2021.*

*Tim participated in the BEQVEZ clinical study.

style

No-padding

Gene therapy may help remove the need for factor IX prophylaxis (FIX prophy)^†

The facts

Living with hemophilia B, depending on the severity, you may infuse FIX as often as 2 times per week, but may still need to treat on demand.

Gene therapy may help remove the need for FIX prophy by helping your body make its own clotting factor.

That means instead of infusing routinely, you may have bleed protection after just one infusion of BEQVEZ.^†

^†Individual results and duration of effect may vary. The main BEQVEZ study is ongoing to assess the long-term efficacy and safety of BEQVEZ. On-demand FIX may still be required.

Tim, an actual BEQVEZTM (fidanacogene elaparvovec- dzkt) patient, being filmed by his wife

Committed to the hemophilia community for over 25 years

From providing safety innovations…
to delivering bleed control and prevention…
to discovering novel treatment options…
and offering people with hemophilia the chance to live differently

Breakthroughs in science, changing people’s lives, brought to you by a leader in clinical research

style

No-padding

prev-page

next-page